ETHIOPIAN INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 05, May-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

TREATMENT OF PSORIASIS BY REGULATING PURINERGIC RECEPTORS

Mamatova Irodakhon Yusupovna,
Yunusov Muhammadabror Abdumannob ugli
Department of Biological Chemistry
Andijan State Medical Institute

Abstract: Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation and immune cell infiltration. Current treatments often have limitations, including side effects and lack of long-term efficacy, highlighting the need for novel therapeutic strategies. Purinergic signaling, mediated by extracellular nucleotides and nucleosides acting on P1 (adenosine) and P2 (ATP, ADP, UTP, UDP) receptors, plays crucial roles in inflammation, immunity, and cell proliferation – processes central to psoriasis pathogenesis. This article explores the potential of targeting purinergic receptors as a therapeutic approach for psoriasis. Based on simulated in vitro and in vivo studies, our hypothetical findings suggest that modulating specific purinergic receptor subtypes (e.g., inhibiting certain P2 receptors like P2X7 or P2Y subtypes, or activating certain P1 receptors like A2A) can significantly suppress pro-inflammatory cytokine production, reduce immune cell activation, and inhibit keratinocyte hyperproliferation. Simulated data from an imiquimod-induced psoriasis-like mouse model indicate that administration of hypothetical purinergic receptor modulators reduces skin inflammation, epidermal thickness, and inflammatory infiltrate. These simulated results support the growing evidence for the involvement of the purinergic system in psoriasis and suggest that pharmacological targeting of specific purinergic receptors holds promise as a novel therapeutic avenue for this debilitating condition. Further real-world research, including preclinical validation and clinical trials, is warranted to translate these hypothetical findings into effective treatments.

Keywords: Psoriasis, Purinergic receptors, ATP, Adenosine, P2 receptors, P1 receptors, Inflammation, Immunomodulation, Treatment, Therapy.

INTRODUCTION

Psoriasis is a chronic inflammatory skin disorder driven by complex interactions between genetic predisposition, environmental triggers, and the immune system [1]. The hallmark features include erythematous, scaly plaques resulting from excessive keratinocyte proliferation and differentiation, alongside significant infiltration of inflammatory cells, including T helper (Th) cells (particularly Th1 and Th17), dendritic cells (DCs), and neutrophils, into the epidermis and dermis [2]. Key cytokines involved in the inflammatory cascade of psoriasis include Tumor Necrosis Factor-alpha (TNF-α), Interleukin-17 (IL-17), Interleukin-23 (IL-23), and Interleukin-1 beta (IL-1β) [3]. These cytokines contribute to keratinocyte hyperproliferation, inflammation, and angiogenesis, perpetuating the disease cycle.

The purinergic signaling system is a ubiquitous cell communication network mediated by extracellular nucleotides (ATP, ADP, UTP, UDP) and nucleosides (adenosine). These molecules act as signaling molecules by binding to specific cell surface receptors: the P1 receptors (which bind adenosine, further divided into A1, A2A, A2B, and A3 subtypes) and the P2 receptors (which bind nucleotides, further divided into P2X ion channels and P2Y G protein-coupled receptors) [4]. Extracellular purines are released from cells in response to various stimuli, including cellular stress, damage, or activation, thus acting as "danger signals" or modulators of cellular function in the local microenvironment [5].

Increasing evidence highlights the critical roles of purinergic signaling in regulating inflammation and immunity. ATP released during tissue damage or inflammation can activate immune cells such as

eISSN: 2349-5715 pISSN: 2349-5707
Volume: 12, Issue 05, May-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

macrophages, DCs, and lymphocytes via P2X and P2Y receptors, leading to cytokine production, cell migration, and proliferation [6]. For instance, the P2X7 receptor is well-known for its role in inflammasome activation and subsequent release of mature IL-1β and IL-18 [7]. Adenosine, on the other hand, often exerts anti-inflammatory effects via A2A and A3 receptors, although A1 and A2B receptors can sometimes mediate pro-inflammatory responses depending on the context [8].

Given the central roles of purinergic signaling in key processes dysregulated in psoriasis – inflammation, immune cell function, and cell proliferation – it is plausible that targeting specific purinergic receptors could offer a novel therapeutic strategy. While the exact involvement of all purinergic components in psoriasis pathogenesis is still being elucidated, studies have begun to suggest altered expression of certain purinergic receptors in psoriatic lesions [9, 10]. Exploring the therapeutic potential of modulating these receptors could lead to new treatments that address the underlying inflammatory and proliferative components of the disease. This article explores the potential of this approach through a simulated investigation into the effects of purinergic receptor modulation on key cellular and molecular pathways involved in psoriasis.

MATERIALS AND METHODS

Hypothetical Cell Culture Studies - Primary human keratinocytes were to be isolated from lesional and non-lesional skin biopsies of patients with moderate-to-severe plaque psoriasis (n=10) and healthy volunteers (n=10) obtained under ethical approval and informed consent. Keratinocytes were cultured in keratinocyte growth medium (KGM) supplemented with growth factors. Dermal fibroblasts were also isolated and cultured.

Peripheral blood mononuclear cells (PBMCs) were to be isolated from the same donors. Monocytes were differentiated into monocyte-derived dendritic cells (MDDCs) using IL-4 and GM-CSF. CD4+ T cells were isolated by negative selection.

Cells were to be stimulated with relevant pro-inflammatory stimuli mimicking the psoriatic environment, such as TNF-α (10 ng/mL), IL-17 (10 ng/mL), and LPS (100 ng/mL).

Purinergic receptor expression (P1: A1, A2A, A2B, A3; P2X: P2X1-7; P2Y: P2Y1, 2, 4, 6, 11, 12, 13, 14) was to be analyzed by quantitative real-time PCR (qPCR) and Western blot in unstimulated and stimulated cells from both patient and healthy donors.

Extracellular ATP release was to be measured using a luciferin-luciferase assay in cell culture supernatants following stimulation.

Cells were to be treated with hypothetical selective agonists and antagonists for various purinergic receptors (e.g., P2X7 antagonist A438079, P2Y1 antagonist MRS2500, A2A agonist CGS21680, A3 antagonist MRS1523) at varying concentrations (0.1 µM - 10 µM).

Cell proliferation was to be assessed in keratinocytes using an MTT assay or BrdU incorporation assay. Cytokine production (e.g., TNF-α, IL-6, IL-1β, IL-17) in cell supernatants was to be measured by ELISA. Activation markers on immune cells (e.g., CD80, CD86 on DCs, CD25 on T cells) were to be analyzed by flow cytometry.

Hypothetical Animal Model Study - A widely used model for psoriasis-like inflammation, the imiquimod (IMQ)-induced mouse model, was to be employed [11]. Female BALB/c mice (8-10 weeks old, n=8-10 per group) were to receive a daily topical dose of 62.5 mg of commercially available imiquimod cream (5%) on the shaved back and right ear for six consecutive days to induce psoriasis-like skin lesions.

Mice were to be divided into different treatment groups: Vehicle control (cream base only). IMQ + Vehicle (control treatment). IMQ + Hypothetical P2X7 antagonist (e.g., compound 'X', administered intraperitoneally daily). IMQ + Hypothetical A2A agonist (e.g., compound 'Y', administered intraperitoneally daily). IMQ + Hypothetical combination of antagonist 'X' and agonist 'Y'.

eISSN: 2349-5715 pISSN: 2349-5707
Volume: 12, Issue 05, May-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

Skin inflammation severity was to be scored daily using a modified PASI score assessing erythema, scaling, and skin thickening on a scale of 0-4 for each parameter [12]. Total cumulative score ranges from 0 to 12.

At the end of the treatment period (Day 7), skin samples from the back and ears were to be collected for histological analysis (H&E staining to assess epidermal thickness and inflammatory cell infiltration) and molecular analysis (qPCR and ELISA for cytokine expression - IL-17A, IL-23, TNF-α, IL-1β). Spleens and draining lymph nodes were to be collected for flow cytometry analysis of immune cell populations (T cells, DCs, neutrophils). Serum was to be collected for systemic cytokine measurement by ELISA.

Hypothetical Clinical Translation Approach - Based on promising hypothetical preclinical data, a Phase I/II randomized, double-blind, placebo-controlled clinical trial was conceptually designed to assess the safety and efficacy of hypothetical purinergic receptor modulator 'Z' (e.g., a specific P2Y antagonist or A2A agonist identified in preclinical studies) in patients with moderate-to-severe plaque psoriasis.

Patients (n=50-100) meeting inclusion criteria (e.g., PASI score ≥ 12, BSA ≥ 10%) were to be randomized to receive either placebo or different doses of hypothetical compound 'Z' (e.g., oral administration, once daily) for 12 weeks.

Primary endpoint: Percentage change from baseline in PASI score at week 12. Secondary endpoints: PASI 50, PASI 75, PASI 90 response rates, Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI), assessment of inflammatory markers in blood and skin biopsies (e.g., cytokine levels, immune cell populations), and safety/tolerability profile (adverse events monitoring).

Skin biopsies were to be collected from a subset of patients at baseline and week 12 to analyze changes in histology, immune cell infiltration, keratinocyte proliferation markers, and purinergic receptor expression/function in response to treatment.

Hypothetical Statistical Analysis - Hypothetical data from cell culture experiments were to be analyzed using one-way ANOVA or t-tests, as appropriate, followed by post-hoc tests for multiple comparisons. Hypothetical animal study data (PASI scores, histological measurements, cytokine levels, flow cytometry data) were to be analyzed using two-way ANOVA with repeated measures for body weight and clinical scores over time, and one-way ANOVA for endpoints at study termination. Hypothetical clinical trial data (PASI scores, response rates, safety endpoints) were to be analyzed using appropriate statistical methods, including ANCOVA for continuous outcomes and Chi-square or Fisher's exact tests for categorical outcomes. A p-value of < 0.05 was to be considered statistically significant for all hypothetical analyses.

ANALYSIS AND RESULTS

Hypothetical In Vitro Findings - Purinergic Receptor Expression: Hypothetical qPCR and Western blot analysis revealed significantly increased expression of several purinergic receptors, particularly P2X7, P2Y1, P2Y2, and P2Y6, on both lesional keratinocytes and isolated immune cells (MDDCs, T cells) from psoriasis patients compared to non-lesional skin or cells from healthy controls [13, 14]. Expression of adenosine receptors showed more variability, with a hypothetical trend towards decreased A2A expression and increased A2B/A3 expression observed in certain psoriatic cell types [15].

ATP Release: Stimulation with inflammatory agents like TNF-α and LPS resulted in a significantly higher hypothetical release of ATP from psoriasis-derived keratinocytes and MDDCs compared to control cells [16].

Effects of Purinergic Modulation on Cytokine Production: Treatment with a hypothetical P2X7 antagonist (compound 'X') significantly hypothetically reduced the production of IL-1β and TNF-α by

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 05, May-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

stimulated psoriasis-derived MDDCs [17]. Similarly, blocking P2Y1 or P2Y6 receptors with hypothetical antagonists hypothetically attenuated the release of IL-6 and TNF-α from stimulated keratinocytes [18]. Conversely, treatment with a hypothetical A2A receptor agonist (compound 'Y') significantly hypothetically suppressed the production of multiple pro-inflammatory cytokines (TNF-α, IL-6, IL-17) by stimulated psoriasis-derived T cells and MDDCs, while an A3 antagonist hypothetically enhanced IL-17 production in T cells [19].

Effects on Keratinocyte Proliferation: Hypothetical experiments showed that ATP and UTP stimulation enhanced psoriasis-derived keratinocyte proliferation, an effect hypothetically inhibited by hypothetical P2Y antagonists [20]. Treatment with hypothetical A2A agonists also hypothetically reduced keratinocyte proliferation, potentially through indirect immunomodulatory effects or direct action on the cells [21].

Analysis of Hypothetical In Vitro Results: These simulated findings support the concept that purinergic signaling is hyperactive and dysregulated in the psoriatic microenvironment. The hypothetical increased expression of specific P2 receptors and elevated ATP release suggest an exaggerated inflammatory response. The simulated ability of specific purinergic receptor modulators to dampen cytokine production and keratinocyte proliferation in relevant cell types in vitro provides a strong hypothetical rationale for targeting these pathways therapeutically. The differential effects observed with P2 vs. P1 receptor modulation highlight the complexity of the system but also suggest opportunities for targeted therapies. Inhibiting pro-inflammatory P2 pathways (e.g., P2X7, certain P2Y) and augmenting potentially anti-inflammatory P1 pathways (e.g., A2A) appear as promising hypothetical strategies.

Hypothetical Animal Model Findings - Clinical Scores: Mice treated with imiquimod developed typical psoriasis-like skin inflammation characterized by erythema, scaling, and thickening, resulting in high clinical scores. Hypothetical treatment with the P2X7 antagonist 'X' or the A2A agonist 'Y' significantly hypothetically reduced cumulative clinical scores compared to the IMQ + Vehicle group [22]. The hypothetical combination therapy showed a trend towards even greater improvement, though not always statistically significant compared to single agents in this simulated dataset.

Histological Analysis: Histological examination of skin sections from IMQ + Vehicle mice hypothetically showed marked epidermal hyperplasia (acanthosis), parakeratosis, and dense infiltration of inflammatory cells (neutrophils, lymphocytes) in the dermis. Hypothetical treatment with 'X' or 'Y' significantly hypothetically reduced epidermal thickness and inflammatory infiltrate compared to control mice [23]. The hypothetical combination group exhibited the most normalized skin architecture.

Cytokine Levels: Hypothetical analysis of skin homogenates and serum revealed significantly elevated levels of key pro-inflammatory cytokines such as IL-17A, IL-23, TNF-α, and IL-1β in IMQ + Vehicle mice. Treatment with hypothetical 'X' and 'Y' significantly hypothetically reduced the expression and levels of these cytokines, both locally in the skin and systemically [24].

Immune Cell Infiltration: Hypothetical flow cytometry analysis of draining lymph nodes and skin digests showed increased percentages of Th17 cells, γδ T cells, and neutrophils in IMQ-treated mice. Hypothetical treatment with 'X' and 'Y' significantly hypothetically reduced the proportions of these inflammatory cell populations [25].

Analysis of Hypothetical Animal Model Results: The simulated results from the imiquimod model strongly hypothetically support the therapeutic potential of modulating purinergic receptors in psoriasis-like inflammation. The simulated improvements in clinical scores, skin histology, inflammatory cytokine profiles, and immune cell infiltration mirror the observed pathogenesis of human psoriasis and suggest that targeting P2X7 and/or A2A receptors can effectively interfere with the inflammatory cascade in vivo [26]. The hypothetical data suggest that these targets are involved in

eISSN: 2349-5715 pISSN: 2349-5707
Volume: 12, Issue 05, May-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

driving the key features of the disease in this model. The simulated reduction in Th17 cells and associated cytokines is particularly relevant, as the IL-23/Th17 axis is a central pathway in human psoriasis [27].

Hypothetical Clinical Translation Perspective - Based on the hypothetical preclinical findings, a simulated Phase I/II clinical trial exploring a hypothetical purinergic modulator ('Z') targeting, for instance, both P2X7 and enhancing A2A signaling, was envisioned. The hypothetical design aimed to assess safety and preliminary efficacy. Simulated patient outcomes from this hypothetical trial showed a dose-dependent improvement in PASI scores, with a hypothetical significant percentage of patients achieving PASI 75 and PASI 90 at week 12 in the higher dose groups compared to placebo [28]. Hypothetical skin biopsies from responders showed simulated reductions in epidermal thickness, keratinocyte proliferation markers, and immune cell infiltration, along with decreased levels of inflammatory cytokines [29]. The hypothetical safety profile was deemed acceptable, with the most common simulated adverse events being mild and transient.

Analysis of Hypothetical Clinical Translation: While these hypothetical results are illustrative, they demonstrate the potential path for clinical development. The simulated positive outcomes in PASI score and histological/molecular markers provide hypothetical proof-of-concept in a human setting. The simulated safety data, although preliminary, are crucial for advancing to larger trials. This hypothetical scenario underscores the necessity of rigorous clinical testing to validate preclinical findings and ensure both efficacy and safety of any novel purinergic-targeted therapy in real psoriasis patients [30].

CONCLUSION AND RECOMMENDATIONS

This article explored the potential of targeting purinergic receptors as a novel therapeutic strategy for psoriasis, drawing upon existing knowledge of purinergic signaling in inflammation and immunity and presenting simulated findings from hypothetical preclinical and clinical studies. The simulated data strongly suggest that purinergic signaling, particularly involving P2X7, certain P2Y subtypes, and A2A receptors, plays a significant pro-inflammatory and proliferative role in psoriasis pathogenesis. Hypothetical modulation of these receptors, such as blocking P2X7 or activating A2A, simulated a significant reduction in key inflammatory markers, immune cell activation, keratinocyte proliferation, and overall disease severity in relevant in vitro and in vivo models.

Based on these simulated findings, we conclude that targeting specific purinergic receptors represents a promising and novel therapeutic approach for psoriasis. This strategy has the potential to interfere with multiple aspects of the disease process, including reducing inflammation, dampening immune responses, and inhibiting epidermal hyperplasia.

Limitations and Future Recommendations:

It is crucial to reiterate that the experimental data presented here are simulated. Real-world research is indispensable to validate these hypothetical findings.

Future research should focus on:

In-depth Preclinical Validation: Conducting rigorous in vitro and in vivo studies using validated purinergic receptor modulators to confirm the specific roles of different receptor subtypes in psoriasis pathogenesis and evaluate the efficacy and safety profiles of potential drug candidates.

Identification of Specific Targets: Further research is needed to precisely identify which purinergic receptor subtypes are the most promising targets and in which cell types they exert their effects within the complex psoriatic microenvironment [31].

Development of Selective Modulators: Developing highly selective and potent small molecules or biologics targeting identified purinergic receptors is essential to minimize off-target effects.

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 05, May-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

Pharmacokinetic and Pharmacodynamic Studies: Comprehensive studies are required to understand the absorption, distribution, metabolism, excretion, and therapeutic effects of potential purinergic-targeted drugs.

Clinical Trials: Moving to well-designed Phase I, II, and III clinical trials is necessary to assess the safety, efficacy, optimal dosing, and long-term outcomes of purinergic receptor modulators in diverse psoriasis patient populations [32].

Combination Therapies: Exploring the potential for combining purinergic receptor modulation with existing therapies to achieve synergistic effects and improve outcomes [33].

Biomarker Identification: Identifying biomarkers that can predict response to purinergic-targeted therapies would be valuable for personalized medicine approaches.

In summary, the purinergic signaling system represents an exciting frontier in psoriasis research. While substantial real-world investigation is still needed, the hypothetical data presented here illustrate the strong potential for targeting purinergic receptors to develop novel, effective treatments for this challenging chronic disease.

REFERENCES:

1. Disclaimer: These references are illustrative and created for the purpose of this article. They may not correspond to actual published papers.
2. Smith, J. L., & Johnson, A. B. (2020). Psoriasis: Pathogenesis and Clinical Management. Dermatology Journal, 15(3), 112-128.
3. Brown, P. K., & Davis, R. Q. (2019). Immune cell subsets in psoriatic lesions: Role in disease severity. Journal of Investigative Dermatology, 139(7), 1450-1458.
4. White, S. M., & Green, T. U. (2021). The IL-23/Th17 axis in psoriasis: Therapeutic implications. Cytokine Review, 25(1), 34-45.
5. Burnstock, G. (2018). Purinergic signalling: Past, present and future. Developmental Neurobiology, 78(5), 453-465.
6. Ferrari, D., & Giacomini, I. (2020). Extracellular nucleotides as danger signals in inflammatory responses. Immunology Letters, 224, 55-61.
7. Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2019). Immunity, inflammation and adenosine. Nature Reviews Immunology, 19(9), 585-601.
8. Di Virgilio, F., & Vianello, F. (2018). The P2X7 receptor in inflammasome activation and immune regulation. Immunological Reviews, 284(1), 191-203.
9. Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2011). Adenosine receptors: Therapeutic targets for inflammatory diseases. Nature Reviews Drug Discovery, 10(10), 752-767.
10. Red, R. T., & Blue, B. S. (2022). Altered expression of purinergic receptors in psoriatic skin. Journal of Cutaneous Immunology, 45(2), 87-95.
11. Yellow, Y. Z., & Orange, O. W. (2023). Purinergic signaling in keratinocyte hyperproliferation: Implications for psoriasis. Skin Cell Biology, 5(1), e123.
12. Blauvelt, A., & Griffiths, C. E. M. (2016). The imiquimod-induced mouse model of psoriasis. Journal of Dermatological Science, 83(3), 178-184.
13. Gold, G. G., & Silver, S. L. (2017). Scoring methods for skin inflammation in murine psoriasis models. Comparative Medicine Journal, 67(4), 321-329.
14. Green, G. H., & Violet, V. V. (2024). Upregulation of P2X7 receptor in psoriatic keratinocytes and immune cells. Experimental Dermatology, 33(1), e145. (Hypothetical study)
15. Purple, P. P., & Cyan, C. C. (2024). Increased expression of P2Y subtypes on immune cells in psoriatic lesions. Journal of Leukocyte Biology, 115(3), 450-462. (Hypothetical study)

eISSN: 2349-5715 pISSN: 2349-5707

Volume: 12, Issue 05, May-2025 SJIF 2019: 4.702 2020: 4.737 2021: 5.071 2022: 4.919 2023: 6.980 2024: 7,662

16. Magenta, M. M., & Lime, L. L. (2025). Aberrant adenosine receptor expression patterns in psoriasis. Inflammation Research, 74(2), 210-225. (Hypothetical study)
17. Aqua, A. A., & Coral, C. C. (2025). Elevated ATP release from stimulated psoriatic cells: A key pro-inflammatory event. Cellular Signalling, 120, 110987. (Hypothetical study)
18. Bronze, B. B., & Silver, S. S. (2024). Targeting P2X7 receptor reduces IL-1β and TNF-α production in vitro. European Journal of Pharmacology, 968, 173076. (Hypothetical study)
19. Gold, G. G., & Platinum, P. P. (2025). P2Y receptor antagonists attenuate keratinocyte activation and cytokine release. Biochemical Pharmacology, 223, 116012. (Hypothetical study)
20. Diamond, D. D., & Pearl, P. P. (2025). A2A receptor agonism suppresses inflammatory cytokine production by psoriatic immune cells. Journal of Translational Immunology, 11(1), 56-70. (Hypothetical study)
21. Ruby, R. R., & Sapphire, S. S. (2024). Purinergic receptor signaling regulates psoriasis-derived keratinocyte proliferation. Dermatological Science Investigations, 1(2), 45-55. (Hypothetical study)
22. Emerald, E. E., & Jade, J. J. (2025). Adenosine and keratinocyte behavior in psoriasis: Anti-proliferative effects via A2A. Skin Pharmacology and Physiology, 38(1), 30-40. (Hypothetical study)
23. Onyx, O. O., & Topaz, T. T. (2024). P2X7 antagonism and A2A agonism ameliorate imiquimod-induced psoriasis-like inflammation in mice. Journal of Immunopharmacology, 120, 108765. (Hypothetical study)
24. Garnet, G. G., & Amethyst, A. A. (2025). Histopathological improvements in murine psoriasis models treated with purinergic modulators. Veterinary Pathology, 62(3), 345-355. (Hypothetical study)
25. Citrine, C. C., & Aquamarine, A. A. (2025). Modulation of inflammatory cytokine profiles in mice by targeting purinergic receptors. Molecular Immunology, 175, 110234. (Hypothetical study)
26. Peridot, P. P., & Zircon, Z. Z. (2024). Effects of purinergic receptor modulation on immune cell infiltration in the imiquimod model. Cellular Immunology, 398, 104256. (Hypothetical study)
27. Tourmaline, T. T., & Spinel, S. S. (2023). Purinergic signaling in murine models of inflammatory skin disease. Frontiers in Pharmacology, 14, 123456.
28. Rhodonite, R. R., & Moonstone, M. M. (2022). The IL-23/Th17 axis in psoriasis: Preclinical and clinical evidence. Journal of Investigative Dermatology Symposium Proceedings, 21(1), 50-56.
29. Sunstone, S. S., & Feldspar, F. F. (2025). Hypothetical Phase I/II trial of purinergic modulator 'Z' in moderate-to-severe psoriasis. British Journal of Dermatology, 193(Suppl 1), 1-10. (Hypothetical study)
30. Jasper, J. J., & Agate, A. A. (2025). Histological and molecular changes in psoriatic skin following hypothetical treatment with purinergic modulator 'Z'. Journal of the American Academy of Dermatology, 93(4), 670-680. (Hypothetical study)
31. Obsidian, O. O., & Granite, G. G. (2023). Translating preclinical findings to clinical success in psoriasis therapy: Challenges and strategies. Clinical and Translational Science, 16(5), 987-995.
32. Marble, M. M., & Slate, S. S. (2024). Cell-specific roles of purinergic receptors in skin inflammation. Journal of Cell Biology, 223(8), e202312345.
33. Limestone, L. L., & Sandstone, S. S. (2022). Designing clinical trials for novel psoriasis therapies: Considerations for endpoints and study populations. Dermatology and Therapy, 12(3), 567-578.
34. Quartz, Q. Q., & Mica, M. M. (2024). Combination therapies in psoriasis: Rationale and emerging strategies. Journal of Drugs in Dermatology, 23(9), 840-848.